Vaccine Info

SKYCovione COVID-19 Vaccine

Authored by
Staff
Last reviewed
July 8, 2022
Fact checked by
Robert Carlson, MD
Share

SKYCovione COVID-19 Vaccine Description

SKYCovione, a protein-based vaccine, was developed at the University of Washington School of Medicine and has been approved by the Korean Ministry of Food and Drug Safety for use in individuals 18 years of age and older.

SKYCovione is made of proteins that form tiny particles studded with fragments of the pandemic coronavirus. These nanoparticles were designed by scientists at UW Medicine and advanced into clinical trials by SK bioscience and GlaxoSmithKline with financial support from the Coalition for Epidemic Preparedness Innovations.

SKYCovione includes GlaxoSmithKline’s pandemic adjuvant, AS03.

SKYCovione was found to be more effective than the Oxford/AstraZeneca vaccine sold under the brand names Covishield and Vaxzevria.

SK bioscience, the company leading SKYCovione’s clinical development abroad, is now seeking approval for its use in the United Kingdom and beyond.

If approved by the World Health Organization, the vaccine will be made available through COVAX, an international effort to distribute COVID-19 vaccines around the world equitably.

In addition, the South Korean government has agreed to purchase 10 million doses for domestic use.

SKYCovione Indication

SKYCovione is indicated to prevent the disease COVID-19 caused by the SRS-Cov-2 virus. 

“This vaccine was designed at the molecular level to present the immune system with a key part of the coronavirus spike protein. We know this part, called the receptor-binding domain, is targeted by the most potent antibodies,” said Neil King, an assistant professor of biochemistry at UW Medicine and co-developer of the vaccine.

SKYCovione News

June 29, 2022 - COVID-19 vaccine with IPD nanoparticles wins full approval abroad. The Seattle scientists behind the new vaccine sought to create a ‘second-generation’ COVID-19 vaccine that is safe, effective at low doses, simple to manufacture, and stable without deep freezing. These attributes could enable vaccination on a global scale by reaching people in areas where medical, transportation, and storage resources are limited.

SKYCovione Clinical Trials

A Phase 3 clinical trial, Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19), compared the immunogenicity and safety of SKYCovione recombinant nanoparticle vaccine adjuvanted with AS03 (GBP510) to Oxford/AstraZeneca vaccine Covishield/Vaxzevria in adults aged 18 years and older.

The results indicated that SKYCovione elicits roughly three times more neutralizing antibodies than the Oxford/AstraZeneca vaccine Covishield/Vaxzevria. In these studies, SKYCovione or Covishield/Vaxzevria was administered twice with an interval of four weeks.

In the Phase 3 trial, there were again no serious adverse reactions to the vaccine.

Phase 1/2 trial results announced by SK bioscience last November and posted as a preprint found that SKYCovione was safe and produced virus-neutralizing antibodies in all trial participants receiving the adjuvanted vaccine. 

Clinical Trials

No clinical trials found